US2015374843A1PendingUtilityA1

Multivalent constructs for therapeutic and diagnostic applications

62
Assignee: BRACCO SUISSE SAPriority: Mar 1, 2002Filed: Apr 17, 2015Published: Dec 31, 2015
Est. expiryMar 1, 2022(expired)· nominal 20-yr term from priority
Inventors:Hong FanKaren E. LinderEdmund R. MarinelliPalaniappa NanjappanAdrian D. NunnRadhakrishna K. PillaiKondareddiar RamalingamAjay ShrivastavaBo SongRolf E. SwensonMathew A. Von WronskiAaron SatoSharon Michele WalkerDaniel T. Dransfield
A61K 38/16A61K 47/48246A61K 47/42Y02A50/30A61K 49/221A61K 47/64C07K 7/08C07K 7/64A61K 47/60A61K 49/223
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods for therapeutic and diagnostic applications.

Claims

exact text as granted — not AI-modified
1 . A compound comprising at least two binding moieties having specificity for different binding sites on the same target. 
     
     
         2 . The compound of  claim 1 , wherein said compound is a multimeric compound comprising a plurality of binding moieties. 
     
     
         3 . The compound of  claim 1 , wherein said compound is a dimeric compound. 
     
     
         4 . The compound of  claim 1 , wherein at least one of the binding moieties comprises a polypeptide. 
     
     
         5 . The compound of  claim 4 , wherein all of the binding moieties comprise polypeptides. 
     
     
         6 . The compound of  claim 5 , wherein the affinity of the compound for the target is about 60 fold greater than the affinity of any one of the polypeptides for the target. 
     
     
         7 . The compound of  claim 5 , wherein the affinity of the compound for the target is about 560 fold greater than the affinity of any one of the polypeptides for the target. 
     
     
         8 . The compound of  claim 4 , wherein each polypeptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12. 
     
     
         9 . The compound of  claim 4 , wherein each polypeptide is selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 27, SEQ NO: 28, and SEQ ID NO: 29. 
     
     
         10 . The compound of  claim 8 , wherein the polypeptide comprises an amino acid substitution, and amide bond substitution, a D-amino acid substitution, a glycosylated amino acid, a disulfide mimetic substitution, an amino acid translocation, a retroinverso peptide, a peptoid, a retro-inverso peptoid, or a synthetic peptide. 
     
     
         11 . The compound of  claim 1 , wherein the target is a protein. 
     
     
         12 . The compound of  claim 1 , wherein the target is a receptor or a receptor/ligand complex. 
     
     
         13 . The compound of  claim 11 , wherein the binding moieties bind to different epitopes on the protein. 
     
     
         14 . The compound of  claim 12 , wherein the binding moieties bind to different epitopes on the receptor or receptor/ligand complex. 
     
     
         15 . The compound of  claim 11 , wherein said target is a receptor involved in angiogenesis. 
     
     
         16 . The compound of  claim 12 , wherein said receptor is a protein-tyrosine kinase receptor. 
     
     
         17 . The compound of  claim 1 , wherein the target comprises KDR or KDR/VEGF complex. 
     
     
         18 . The compound of  claim 17 , wherein the binding moieties bind to different epitopes on KDR or KDR/VEGF complex. 
     
     
         19 . The compound of  claim 11 , wherein said target is a receptor involved in hyperproliferation. 
     
     
         20 . The compound of  claim 11 , wherein said target is a receptor expressed on a tumor. 
     
     
         21 .- 112 . (canceled)

Join the waitlist — get patent alerts

Track US2015374843A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.